Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
a study on Percutaneous Coronary Intervention Coronary Artery Disease Peripheral Artery Disease
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA UCSD
- Dates
- study startedstudy ends around
Description
Summary
To test whether FFRangio-guided treatment is non-inferior to conventional pressure wire-guided treatment in patients with coronary artery disease.
Details
ALL-RISE is a prospective, randomized, multi-center, controlled post-market study. The ALL-RISE study is designed to test whether FFRangio-guided treatment is non-inferior to conventional pressure wire-guided treatment in patients with coronary artery disease being evaluated for percutaneous coronary intervention (PCI) with respect to major adverse cardiac events (MACE) at one year.
Keywords
Percutaneous Coronary Intervention, PCI, Coronary Artery Disease, FFRangio, Pressure Wire-Guided, FFR or NHPR, Pressure wire
Eligibility
You can join if…
Open to people ages 18 years and up
- Adult patients (≥18 years of age) with one or more study lesion(s) (diameter stenosis 50-90%) deemed appropriate for both pressure-wire and FFRangio physiologic assessment.
General
You CAN'T join if...
- Subject with ST-elevation (MI (STEMI) within 72 hours at time of study enrollment
- Prior coronary artery bypass graft (CABG) with patent grafts to the study vessel(s)
- Patients undergoing coronary physiologic assessment where one possible outcome is referral for CABG
- The study vessel supplies a significant nonviable territory (e.g., prior transmural MI)
- Severe left sided valvular heart disease
- Most recent documented LVEF ≤30%
- Women who are pregnant or breastfeeding (women of childbearing potential are required to have negative pregnancy test within 1 week of index procedure)
- Patients with life expectancy <1 year life as estimated by treating physician.
- Subjects enrolled in other ongoing non-registry clinical studies that would impact conduct or outcomes of this study (registries and long-term follow-up of other studies are allowed)
- Subjects who have undergone angiographic or wire-based coronary physiological assessment for 1 or more potential study lesions within 30 days of enrollment.
Angiographic Exclusion Criteria:
- Coronary angiogram is not acquired per instructions as defined in the Study Protocol
- Sthe study lesion is the clear culprit for a NSTEACS
- Angiographic evidence of a procedural complication (e.g., acute stent thrombosis, flow-limiting dissection, perforation, slow/no reflow, or other) prior to randomization
- Thrombolysis in myocardial infarction (TIMI) Grade 2 flow or lower in any study vessel at time of enrollment
- The study vessel is in a left coronary vessel with separate left anterior descending and left circumflex ostia arising from the aorta
- The study lesion involves the left main coronary artery (stenosis ≥ 50%)
- The study lesion is in an ectatic or aneurysmal coronary segment (defined as lumen diameter 1.5x diameter or the reference vessel)
Locations
- University of California San Diego Health
La Jolla California 92037 United States - UCLA Medical Center
Los Angeles California 90095 United States - Kaiser Permanente San Francisco
San Francisco California 94118 United States - Keck Medicine of USC
Los Angeles California 90033 United States - VA- Long Beach Healthcare
Long Beach California 90822 United States - Stanford University
Palo Alto California 94305 United States - VA - Palo Alto Healthcare
Palo Alto California 94305 United States
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- CathWorks Ltd.
- ID
- NCT05893498
- Study Type
- Interventional
- Participants
- Expecting 1924 study participants
- Last Updated